rosiglitazone has been researched along with Cicatrix in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, M; Duan, X; Huang, Y; Liu, H; Liu, K; Pan, Z; Zhang, F; Zhou, D | 1 |
| Bühren, J; Ciufo, D; DeMagistris, M; Hindman, HB; Huxlin, KR; Jeon, KI; MacRae, S; Phipps, RP; Sime, PJ | 1 |
2 other study(ies) available for rosiglitazone and Cicatrix
| Article | Year |
|---|---|
Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model.
Topics: Animals; Cicatrix; Conjunctiva; Cornea; Disease Models, Animal; Drug Delivery Systems; Fibrosis; Filtering Surgery; Glaucoma; Intraocular Pressure; Polyesters; Rabbits; Rosiglitazone; Wound Healing | 2019 |
Topical rosiglitazone is an effective anti-scarring agent in the cornea.
Topics: Actins; Administration, Topical; Animals; Cats; Cell Differentiation; Cells, Cultured; Cicatrix; Cornea; Corneal Wavefront Aberration; Drug Evaluation, Preclinical; Myofibroblasts; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Treatment Outcome; Wound Healing | 2013 |